Alpha Tau Medical Ltd · NASDAQ:DRTS
Alpha Tau Medical — Corporate Update (November 2026)
28 slides from Alpha Tau Medical's corporate update, Nov 16, 2026
Slide 1: Alpha DaRT in the brain. Interim results from REGAIN
N A S D A Q / T A S E · D R T S R E G A I N · I N T E R I M R E S U L T S A S O F N O V 1 1 , 2 0 2 6 Alpha DaRT in the brain. Interim results as of November 11, 2026 from REGAIN, the U.S. trial of Alpha DaRT in recurrent glioblastoma, as presented at the SNO 2026 Annual Meeting. 8 of 8 patients ali
Slide 2: Important notices
D I S C L A I M E R Important notices. This presentation (together with oral statements made in connection herewith, the "Presentation") is for informational purposes only to assist interested parties in making their own evaluation with respect to Alpha Tau Medical Ltd. ("Alpha Tau" or the "Company"
Slide 3: Today's presenters
T O D A Y ' S P R E S E N T E R S Today's presenters. 3 Uzi Sofer CEO, Alpha Tau Raphi Levy CFO, Alpha Tau Robert Den, MD Chief Medical Officer, Alpha Tau Joshua Palmer, MD Professor, Radiation Oncology · Principal Investigator, REGAIN Ohio State University Comprehensive Cancer Center - The James Al
Slide 4: What we will cover
A G E N D A What we will cover. 4 01 Alpha DaRT mechanism of action Why alpha radiation, how Alpha DaRT is designed to extend its reach, and the Alpha radial applicator for the brain. 02 Interim results from REGAIN as of Nov 11, 2026 Trial design, feasibility and safety, survival and tumor response,
Slide 5: Alpha DaRT: mechanism of action
0 1 · T H E S C I E N C E Alpha DaRT: mechanism of action. 5
Slide 6: Why alpha radiation. Two kinds of radiation, two kinds of DNA damage
T H E S C I E N C E · W H Y A L P H A Why alpha radiation. Two kinds of radiation, two kinds of DNA damage. 6 Conventional gamma / beta radiation Damages DNA indirectly, through free radicals Dependent on the presence of oxygen Causes repairable single-strand breaks Alpha radiation Damages DNA direc
Slide 7: Cancer's most potent radiation had a range problem
T H E S C I E N C E · T H E P R O B L E M Cancer's most potent radiation had a range problem. 7 <0.1 mm alpha-particle range in tissue: about the width of a human hair Alpha particles are massively destructive at point-blank range and spare what lies beyond it, but they could not reach far enough in
Slide 8: Alpha DaRT: a source designed to extend alpha radiation's reach
T H E S C I E N C E · T H E I N V E N T I O N Alpha DaRT: a source designed to extend alpha radiation's reach. 8 H E A L T H Y T I S S U E T U M O R Ra-224 source daughter atoms disperse millimeters into the tumor Radium-224 Radon-220 Polonium-216 Lead-212 Bismuth-212 Lead-208 (stable) Four alpha em
Slide 9: Alpha DaRT diffusion, animated
T H E S C I E N C E · I N M O T I O N Alpha DaRT diffusion, animated. 9 Animation is a schematic illustration of the intended mechanism; designed to deliver alpha radiation locally. Not drawn to scale.
Slide 10: Slide 10
Slide 11: REGAIN: interim results as of Nov 11, 2026
0 2 · C L I N I C A L · R E G A I N T R I A L · S N O 2 0 2 6 REGAIN: interim results as of Nov 11, 2026. 11
Slide 12: REGAIN trial design
REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY REGAIN trial design. Prospective, interventional, open-label, single-arm study · NCT06910306 · patients treated to date at The Ohio State University Comprehensive Cancer Center 12 20 patients planned s
Slide 13: Key takeaways
REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Interim results as of Nov 11, 2026. Key takeaways · 8 patients treated, 6 reached response assessment 13 PRESENTED AT THE SNO 2026 Annual Meeting · Philadelphia, Nov 12-15 100% feasibility all planned
Slide 14: Primary endpoints: feasibility and safety
REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Primary endpoints: feasibility and safety. Interim results as of Nov 11, 2026 · eight patients treated 14 PRESENTED AT THE SNO 2026 Annual Meeting · Philadelphia, Nov 12-15 100% feasibility Alpha DaRT
Slide 15: Survival: all eight patients are alive
REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Survival: all eight patients are alive. Interim results as of Nov 11, 2026 · follow-up from trial enrollment · six patients who have reached response assessment 15 PRESENTED AT THE SNO 2026 Annual Meet
Slide 16: Response and status by patient
REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Response and status by patient. Interim results as of Nov 11, 2026 · best overall response per RANO on serial MRI 16 PRESENTED AT THE SNO 2026 Annual Meeting · Philadelphia, Nov 12-15 Patient Treated B
Slide 17: Reading the scans: necrosis or recurrence?
REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Reading the scans: necrosis or recurrence? Interim results as of Nov 11, 2026 · why some of the follow-up imaging cannot yet be interpreted. Any necrosis has been asymptomatic 17 PRESENTED AT THE SNO 2
Slide 18: Patient by patient: imaging and clinical course
0 3 · R E G A I N · I N T E R I M R E S U L T S A S O F N O V 1 1 , 2 0 2 6 Patient by patient: imaging and clinical course. 18
Slide 19: Baseline characteristics: six patients
REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Baseline characteristics: six patients. Interim results as of Nov 11, 2026 · all six: WHO grade 4 glioma, IDH wild type · 5 male, 1 female · ages 45 to 71 19 PRESENTED AT THE SNO 2026 Annual Meeting ·
Slide 20: Patient 1: complete response, later progression elsewhere
REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Patient 1: complete response, later progression elsewhere. 56-year-old male · MGMT not assessed · 3 recurrences · enrolled 11/24/2025 · treated 12/05/2025 · follow-up 11.6 months from enrollment 20 PAT
Slide 21: Patient 2: complete response, with necrosis
REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Patient 2: complete response, with necrosis. 71-year-old male · MGMT hypermethylated · 2 recurrences · enrolled 01/12/2026 · treated 02/03/2026 · follow-up 10.0 months from enrollment 21 PATIENT 1 · 2
Slide 22: Patient 3: stable disease converted to complete response
REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Patient 3: stable disease converted to complete response. 56-year-old male · MGMT hypermethylated, at/near assay cutoff · 1 recurrence · enrolled 02/26/2026 · treated 03/27/2026 · follow-up 8.5 months
Slide 23: Patient 4: partial response, now under evaluation
REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Patient 4: partial response, now under evaluation. 57-year-old male · MGMT unmethylated · 1 recurrence · enrolled 06/04/2026 · treated 06/24/2026 · follow-up 5.3 months from enrollment 23 PATIENT 1 · 2
Slide 24: Patient 5: complete response at one month, now under evaluation
REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Patient 5: complete response at one month, now under evaluation. 45-year-old male · MGMT unmethylated · 2 recurrences · enrolled 06/25/2026 · treated 07/08/2026 · follow-up 4.6 months from enrollment 2
Slide 25: Patient 6: complete response at first assessment
REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Patient 6: complete response at first assessment. 71-year-old female · MGMT hypermethylated · 1 recurrence · enrolled 08/10/2026 · treated 09/09/2026 · follow-up 3.1 months from enrollment 25 PATIENT 1
Slide 26: Summary: interim results as of Nov 11, 2026
REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Summary: interim results as of Nov 11, 2026. REGAIN · presented at the SNO 2026 Annual Meeting 26 PRESENTED AT THE SNO 2026 Annual Meeting · Philadelphia, Nov 12-15 What the data show Feasible: all pla
Slide 27: The next few months. Anticipated milestones
A N T I C I P A T E D M I L E S T O N E S The next few months. Anticipated milestones · today's discussion: recurrent GBM 27 H 2 2 0 2 6 H 1 2 0 2 7 Skin: ReSTART pivotal Pancreas: IMPACT pilot GBM: REGAIN pilot Prostate: U.S. pilot Top-line data: Early 2027 → potential FDA submission ✓ Recruitment
Slide 28: Questions?
Questions? alphatau.com · NASDAQ / TASE: DRTS · [email protected] 28